New insights in osteoarthritis diagnosis and treatment: Nano-strategies for an improved disease management
Resumen: Osteoarthritis (OA) is a common chronic joint pathology that has become a predominant cause of disability worldwide. Even though the origin and evolution of OA rely on different factors that are not yet elucidated nor understood, the development of novel strategies to treat OA has emerged in the last years. Cartilage degradation is the main hallmark of the pathology though alterations in bone and synovial inflammation, among other comorbidities, are also involved during OA progression. From a molecular point of view, a vast amount of signaling pathways are implicated in the progression of the disease, opening up a wide plethora of targets to attenuate or even halt OA. The main purpose of this review is to shed light on the recent strategies published based on nanotechnology for the early diagnosis of the disease as well as the most promising nano-enabling therapeutic approaches validated in preclinical models. To address the clinical issue, the key pathways involved in OA initiation and progression are described as the main potential targets for OA prevention and early treatment. Furthermore, an overview of current therapeutic strategies is depicted. Finally, to solve the drawbacks of current treatments, nanobiomedicine has shown demonstrated benefits when using drug delivery systems compared with the administration of the equivalent doses of the free drugs and the potential of disease-modifying OA drugs when using nanosystems. We anticipate that the development of smart and specific bioresponsive and biocompatible nanosystems will provide a solid and promising basis for effective OA early diagnosis and treatment.
Idioma: Inglés
DOI: 10.1002/wnan.1844
Año: 2023
Publicado en: WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 15, 2 (2023), e1844 [35 pp.]
ISSN: 1939-5116

Factor impacto JCR: 6.9 (2023)
Categ. JCR: NANOSCIENCE & NANOTECHNOLOGY rank: 33 / 140 = 0.236 (2023) - Q1 - T1
Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 21 / 189 = 0.111 (2023) - Q1 - T1

Factor impacto SCIMAGO: 1.571 - Bioengineering (Q1) - Nanoscience and Nanotechnology (Q1) - Medicine (miscellaneous) (Q1) - Biomedical Engineering (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII-IIS/MS19-00092
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Ingeniería Química (Dpto. Ing.Quím.Tecnol.Med.Amb.)
Área (Departamento): Área Traumatología y Ortopedia (Dpto. Cirugía)


Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.


Exportado de SIDERAL (2024-07-19-18:37:49)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos



 Registro creado el 2022-10-20, última modificación el 2024-07-20


Versión publicada:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)